<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/'><id>tag:blogger.com,1999:blog-5199522738412628687.post2351886588759547728..comments</id><updated>2012-01-10T13:31:40.428-06:00</updated><category term='mobile'/><category term='med/legal/reg challenges'/><category term='Quality Health'/><category term='measurement'/><category term='warning letters'/><category term='Pharma humor'/><category term='privacy'/><category term='sanofi-aventis'/><category term='analytics'/><category term='UCB'/><category term='epharma'/><category term='FDA'/><category term='Web design'/><category term='PatientsLikeMe'/><category term='pharma marketing'/><category term='ADHD'/><category term='PhRMA Guidelines'/><category term='online media'/><category term='Everyday Health'/><category term='web 3.0'/><category term='DTC'/><category term='emails'/><category term='Med Ad News'/><category term='customer service'/><category term='celebrity spokespeople'/><category term='Prospectiv'/><category term='government'/><category term='Abbott'/><category term='MySpace'/><category term='agency models'/><category term='big agencies'/><category term='Tweetpharm'/><category term='GoInsulin'/><category term='integration'/><category term='ALS'/><category term='FTC'/><category term='Sermo'/><category term='persistence'/><category term='patient-centricity'/><category term='innovation'/><category term='Crossix'/><category term='isi'/><category term='ePharma Summit'/><category term='WebMD'/><category term='DailyStrength'/><category term='conferences'/><category term='segmentation'/><category term='Sidewiki'/><category term='technology'/><category term='Twitter'/><category term='Health Central'/><category term='AdRx'/><category term='brainstorms'/><category term='EyeForPharma'/><category term='SNL skit'/><category term='IT'/><category term='DTC humor'/><category term='ebook'/><category term='creativity'/><category term='vintage pharma'/><category term='Pew'/><category term='MOA'/><category term='SEM'/><category term='social networking'/><category term='Blackberry'/><category term='buzzword bingo'/><category term='planning'/><category term='Wall Street Journal'/><category term='retention'/><category term='Rozerem'/><category term='adherence'/><category term='sharesendsave'/><category term='search marketing'/><category term='learning'/><category term='Facebook'/><category term='Manhattan Research'/><category term='Yahoo'/><category term='hype'/><category term='Genentech'/><category term='Unbranded site strategy'/><category term='ROI'/><category term='coupons'/><category term='Manny Awards'/><category term='social sharing'/><category term='videos'/><category term='unbranded Web sites'/><category term='2010'/><category term='eCRM'/><category term='YouTube'/><category term='Shire'/><category term='FirstWord'/><category term='Google'/><category term='AdAge'/><category term='being a patient'/><category term='user experience design'/><category term='Economy'/><category term='Bing'/><category term='health information seekers'/><category term='digital agency'/><category term='awards'/><category term='compliance'/><category term='public relations'/><category term='independence'/><category term='social media'/><category term='BrandWeek'/><category term='Digital Pharma'/><category term='back pain'/><title type='text'>Comments on ePharma Rx: My Pollyanna View of Recent FDA Guidance</title><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://blog.intouchsol.com/feeds/2351886588759547728/comments/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5199522738412628687/2351886588759547728/comments/default'/><link rel='alternate' type='text/html' href='http://blog.intouchsol.com/2012/01/my-pollyanna-view-of-recent-fda.html'/><author><name>Wendy W. Blackburn</name><uri>http://www.blogger.com/profile/01712567520098554819</uri><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='24' height='32' src='http://3.bp.blogspot.com/_N3mwtdW7vDY/TEXvfAHzL1I/AAAAAAAAALs/futJRotbPjY/S220/Wendy_new_July2010_crop.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>2</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-5199522738412628687.post-1632928192363783124</id><published>2012-01-10T13:31:40.428-06:00</published><updated>2012-01-10T13:31:40.428-06:00</updated><title type='text'>Thanks for your comment, Jason. The discussion is ...</title><content type='html'>Thanks for your comment, Jason. The discussion is certainly something in which Radian6 has a stake. When engaging in and even just monitoring the social space, pharma fears the off-label remark. At least this provides a bit more clarity on if and how pharma should deal those comments. &lt;br /&gt;&lt;br /&gt;Yes - its progress! Thanks for joining my Pollyanna-fest.</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5199522738412628687/2351886588759547728/comments/default/1632928192363783124'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5199522738412628687/2351886588759547728/comments/default/1632928192363783124'/><link rel='alternate' type='text/html' href='http://blog.intouchsol.com/2012/01/my-pollyanna-view-of-recent-fda.html?showComment=1326223900428#c1632928192363783124' title=''/><author><name>Wendy W. Blackburn</name><uri>http://www.blogger.com/profile/01712567520098554819</uri><email>noreply@blogger.com</email><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='OpenSocialUserId' value='17451488262821203649'/><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='24' height='32' src='http://3.bp.blogspot.com/_N3mwtdW7vDY/TEXvfAHzL1I/AAAAAAAAALs/futJRotbPjY/S220/Wendy_new_July2010_crop.jpg'/></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://blog.intouchsol.com/2012/01/my-pollyanna-view-of-recent-fda.html' ref='tag:blogger.com,1999:blog-5199522738412628687.post-2351886588759547728' source='http://www.blogger.com/feeds/5199522738412628687/posts/default/2351886588759547728' type='text/html'/><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='blogger.itemClass' value='pid-3757176'/></entry><entry><id>tag:blogger.com,1999:blog-5199522738412628687.post-4186954742216699539</id><published>2012-01-10T13:07:45.241-06:00</published><updated>2012-01-10T13:07:45.241-06:00</updated><title type='text'>Hi Wendy,

Given the reactions I&amp;#39;ve read in so...</title><content type='html'>Hi Wendy,&lt;br /&gt;&lt;br /&gt;Given the reactions I&amp;#39;ve read in some corners of the web, you may actually get more hits right now with this more optimistic piece. &lt;br /&gt;&lt;br /&gt;I would think most patients can appreciate discussions surrounding their health being moved to more private channels.  &lt;br /&gt;&lt;br /&gt;Overall, I think this SHOULD give Pharma a bit more confidence as far as wading into social media conversations and touching base with people using their products.&lt;br /&gt;&lt;br /&gt;It&amp;#39;s progress.   &lt;br /&gt;&lt;br /&gt;Cheers&lt;br /&gt;&lt;br /&gt;Jason Boies&lt;br /&gt;Radian6 Community Team</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/5199522738412628687/2351886588759547728/comments/default/4186954742216699539'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/5199522738412628687/2351886588759547728/comments/default/4186954742216699539'/><link rel='alternate' type='text/html' href='http://blog.intouchsol.com/2012/01/my-pollyanna-view-of-recent-fda.html?showComment=1326222465241#c4186954742216699539' title=''/><author><name>Jason Boies</name><uri>http://www.radian6.com/</uri><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img1.blogblog.com/img/blank.gif'/></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://blog.intouchsol.com/2012/01/my-pollyanna-view-of-recent-fda.html' ref='tag:blogger.com,1999:blog-5199522738412628687.post-2351886588759547728' source='http://www.blogger.com/feeds/5199522738412628687/posts/default/2351886588759547728' type='text/html'/><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='blogger.itemClass' value='pid-1927403535'/></entry></feed>
